Xie Lin, Zhou Steve, Pinsky Brett W, Buysman Erin K, Baser Onur
1 STATinMED Research , Ann Arbor, Michigan.
Diabetes Technol Ther. 2014 Sep;16(9):567-75. doi: 10.1089/dia.2013.0312. Epub 2014 Apr 15.
Diabetes accounts for almost 15% of all direct healthcare expenditures. Managed care organizations try to reduce costs and improve patient outcomes. Increasing patient persistence with antidiabetes treatment could help achieve these goals.
A retrospective study was conducted using the Optum Research Database (Optum, Eden Prairie, MN) to analyze clinical and economic outcomes associated with initiation of insulin glargine via a disposable pen (GLA-P) or vial and syringe (GLA-V) among adult, insulin-naive patients with type 2 diabetes mellitus (T2DM). Propensity-matched patient cohorts were assessed for persistence with insulin therapy, glycated hemoglobin (A1C), hypoglycemic events (based on diagnosis codes), and healthcare costs (total paid amount of adjudicated claims) after follow-up at 1 year.
In 1,308 matched patients, persistence was significantly higher (P=0.011) and longer (P=0.001) with GLA-P. Follow-up A1C values were significantly lower (P=0.038), and decreases in A1C from baseline significantly larger (P=0.043), in GLA-P than in GLA-V. Significantly fewer hypoglycemic events (P=0.042) were experienced, and a lower rate of diabetes-related inpatient admissions (P=0.008) was reported in GLA-P than GLA-V. Despite higher study drug costs with GLA-P than GLA-V, all-cause and diabetes-related healthcare costs were similar.
In insulin-naive patients with T2DM, initiation of insulin glargine using the disposable pen rather than the vial and syringe is associated with higher persistence, better A1C control, and lower rates of hypoglycemia. The higher study drug costs associated with pen use do not increase total all-cause or diabetes-related healthcare costs. This may help treatment selection for patients with T2DM in a managed care setting.
糖尿病占所有直接医疗支出的近15%。管理式医疗组织试图降低成本并改善患者预后。提高患者对抗糖尿病治疗的依从性有助于实现这些目标。
利用Optum研究数据库(Optum,明尼苏达州伊甸草原市)进行了一项回顾性研究,以分析在成年初治2型糖尿病(T2DM)患者中,通过一次性笔(GLA-P)或小瓶和注射器(GLA-V)起始甘精胰岛素治疗的临床和经济结局。在1年随访后,对倾向匹配的患者队列评估胰岛素治疗的依从性、糖化血红蛋白(A1C)、低血糖事件(基于诊断编码)和医疗费用(已裁决索赔的总支付金额)。
在1308例匹配患者中,GLA-P组的依从性显著更高(P = 0.011)且持续时间更长(P = 0.001)。GLA-P组的随访A1C值显著更低(P = 0.038),且A1C从基线的下降幅度显著更大(P = 0.043)。GLA-P组经历的低血糖事件显著更少(P = 0.042),且糖尿病相关住院率更低(P = 0.008)。尽管GLA-P组的研究药物成本高于GLA-V组,但全因和糖尿病相关医疗费用相似。
在初治T2DM患者中,使用一次性笔而非小瓶和注射器起始甘精胰岛素治疗与更高的依从性、更好的A1C控制和更低的低血糖发生率相关。笔式使用相关的更高研究药物成本并未增加全因或糖尿病相关的总医疗费用。这可能有助于在管理式医疗环境中为T2DM患者选择治疗方案。